Last updated on January 2020

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Brief description of study

This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.

Clinical Study Identifier: NCT03963401

Find a site near you

Start Over

Emeritus Research

Camberwell, Australia
  Connect »

Cabrini Hospital

Malvern, Australia
  Connect »